Stefano Petruzzelli

Learn More
Combination inhalers containing corticosteroids and long-acting β-agonists are used to reduce exacerbation rates in patients with severe chronic obstructive pulmonary disease (COPD). The FORWARD (Foster 48-week Trial to Reduce Exacerbations in COPD) clinical trial in severe COPD patients is a comparison of extrafine beclomethasone dipropionate and(More)
A fixed-dose inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) combination of extrafine beclometasone dipropionate and formoterol fumarate (BDP/FF) has been recently approved for use in chronic obstructive pulmonary disease (COPD). Small airway inflammation and remodelling are cardinal features of COPD; therefore, the ability of this extrafine(More)
BACKGROUND A high strength of beclomethasone/formoterol fumarate (BDP/FF) in a pressurised metered dose inhaler (pMDI), which contains extrafine BDP (200 μg/actuation) and FF (6 μg/actuation) has been developed to treat those asthmatics who are not adequately controlled on previous treatments. METHODS A 12-week, randomized, double-blind, parallel group(More)
An improved high-performance liquid chromatography/fluorometric assay has been established to quantitate the benzo(«)pyrene (BP) tetrols released after acid hydrolysis of lung DN A from lung cancer patients, so that the formation of benzo(a)pyrene diol-epoxide-DNA adducts can be measured. isolated by high-performance liquid chromatography was determined by(More)
  • 1